We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Nasdaq Real Time Price USD

SciSparc Ltd. (SPRC)

0.3590

+0.0700

+(24.18%)

As of 11:11:16 AM EDT. Market Open.

Key Events

Loading Chart for SPRC

Previous Close 0.2890
Open 0.3816
Bid 0.2536 x 200
Ask 0.4576 x 200
Day's Range 0.3514 - 0.5000
52 Week Range 0.1970 - 1.7900
Volume 66,846,497
Avg. Volume 2,559,161
Market Cap (intraday) 3.887M
Beta (5Y Monthly) 0.84
PE Ratio (TTM) --
EPS (TTM) -5.2800
Earnings Date Apr 24, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

2

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc says MitoCareX expands research to pancreatic cancer

Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SPRC

0.28%

S&P 500 (^GSPC)

3.66%

1-Year Return

SPRC

71.51%

S&P 500 (^GSPC)

10.50%

3-Year Return

SPRC

99.48%

S&P 500 (^GSPC)

36.64%

5-Year Return

SPRC

99.75%

S&P 500 (^GSPC)

97.54%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

0.3590

+24.18%

Mkt Cap 3.887M

Industry Biotechnology

Adial Pharmaceuticals, Inc.

0.6785

+1.29%

Mkt Cap 4.461M

Industry Biotechnology

Processa Pharmaceuticals, Inc.

0.2539

+9.67%

Mkt Cap 1.338M

Industry Biotechnology

Impact BioMedical Inc.

0.5824

-22.07%

Mkt Cap 7.039M

Industry Biotechnology

Cardio Diagnostics Holdings, Inc.

0.4412

+3.20%

Mkt Cap 23.007M

Industry Biotechnology

Tevogen Bio Holdings Inc.

1.0204

+1.02%

Mkt Cap 187.644M

Industry Biotechnology

Spruce Biosciences, Inc.

0.0700

+2.19%

Mkt Cap 2.954M

Industry Biotechnology

Cyclacel Pharmaceuticals, Inc.

0.2707

+7.76%

Mkt Cap 56.126M

Industry Biotechnology

Clearmind Medicine Inc.

0.9900

-1.98%

Mkt Cap 5.083M

Industry Biotechnology

Onconetix, Inc.

0.0686

-1.71%

Mkt Cap 997,800

Industry Biotechnology

Hepion Pharmaceuticals, Inc.

0.3272

+14.97%

Mkt Cap 3.591M

Industry Biotechnology

Valuation Measures

    Annual 

As of 5/2/2025

Market Cap

3.13M
Enterprise Value

633.36k
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

0.59
Price/Book (mrq)

0.45
Enterprise Value/Revenue

0.36
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-42.05%
Return on Equity (ttm)

-80.66%
Revenue (ttm)

1.31M
Net Income Avi to Common (ttm)

-6.28M
Diluted EPS (ttm)

-5.2800

Balance Sheet and Cash Flow

Total Cash (mrq)

2.06M
Total Debt/Equity (mrq)

0.51%
Levered Free Cash Flow (ttm)

-8.67M

Revenue vs. Earnings

Revenue --

Earnings --

Q3'17

Q4'17

Q1'21

Q2'21

-3M

-2M

-2M

-1M

-500K

0

Analyst Price Targets

No Analyst Price Targets available for this ticker

CMND Clearmind Medicine Inc.

0.9900

-1.98%

CDIO Cardio Diagnostics Holdings, Inc.

0.4412

+3.20%

PXMD PaxMedica, Inc.

0.0001

0.00%

FRGT Freight Technologies, Inc.

1.5074

-27.53%

SMX SMX (Security Matters) Public Limited Company

1.7450

-3.06%

TGL Treasure Global Inc.

1.9790

-3.48%

SMFL Smart for Life, Inc.

0.0015

+50.00%

VRAX Virax Biolabs Group Limited

1.0050

-1.47%

ZVSA ZyVersa Therapeutics, Inc.

0.6139

-2.10%

ACON Aclarion, Inc.

7.04

+0.28%

BDRX Biodexa Pharmaceuticals Plc

1.4002

+0.73%

TIVC Tivic Health Systems, Inc.

4.2200

-5.38%

INBS Intelligent Bio Solutions Inc.

1.3500

-0.74%

ILAG Intelligent Living Application Group Inc.

0.3801

-2.51%

QNRX Quoin Pharmaceuticals, Ltd.

6.28

+1.62%

REVB Revelation Biosciences, Inc.

2.8500

-0.35%